Hypopigmenting agents: An updated review on biological, chemical and clinical aspects

Pigment Cell Research

Volumn 19, Issue 6, 2006, Pages 550-571

  Solano, Francisco ^a   Briganti, Stefania ^b   Picardo, Mauro ^b   Ghanem, Ghanem ^c  

^a UNIVERSITY OF MURCIA   (Spain)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

Antioxidants; Depigmentation; Flavonoids; Hypopigmentation; Melanocyte; Tyrosinase inhibitors

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETAMETHASONE VALERATE; BUSULFAN; CENTAUREIDINE; CERAMIDE; CORTICOSTEROID; CYCLIC AMP; DERMATOLOGICAL AGENT; FLAVONOID; HYPOPIGMENTING AGENT; IMATINIB; INTERLEUKIN 1; INTERLEUKIN 6; KAEMPFEROL; LINCOMYCIN; LINOLEIC ACID; LINOLENIC ACID; MELANOCORTIN 1 RECEPTOR; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; NICOTINAMIDE; OLEIC ACID; OXYGENASE INHIBITOR; PHOSPHOLIPASE D2; QUERCETIN; RWJ 50353; SERINE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIOXIDANT ACTIVITY; CELL FUNCTION; CHLOASMA; CLINICAL TRIAL; COCULTURE; CYTOTOXICITY; DOWN REGULATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; ENZYME DEGRADATION; ENZYME INHIBITION; GENE MUTATION; HUMAN; HYPOPIGMENTATION; KERATINOCYTE; MAMMAL; MEDICINAL PLANT; MELANOCYTE; MELANOGENESIS; MELANOSOME; NONHUMAN; ONCOGENE; PROTEIN FUNCTION; REVIEW; SKIN ABRASION; SKIN ABSORPTION; SKIN EXFOLIATION; VALIDATION STUDY;

MAMMALIA;

EID: 33750538670     PISSN: 08935785     EISSN: 16000749     Source Type: Journal    
DOI: 10.1111/j.1600-0749.2006.00334.x     Document Type: Review

References (229)

1. Abdel-Malek, Z.A., Scott, M.C., Furumura, M., Lamoreux, M.L., Ollmann, M., Barsh, G.S., and Hearing, V.J. (2001). The melanocortin 1 receptor is the principal mediator of the effects of agouti signaling on mammalian melanocytes. J. Cell Sci. 114, 1019-1024.
2. Amer, M., and Metwalli, M. (2000). Topical liquiritin improves melasma. Int. J. Dermatol. 39, 299-301.
3. Ando, H., Itoh, A., Mishima, Y., and Ichihashi, M. (1995). Correlation between the number of melanosomes, tyrosinase mRNA levels and tyrosinase activity in cultured murine melanoma cells in response to various melanogenesis regulatory agents. J. Cell. Physiol. 163, 608-614.
4. Ando, H., Ryu, A., Hashimoto, A., Oka, M., and Ichashi, M. (1998). Linoleic and α-linolenic acids lighten UV-induced hyperpigmentation of the skin. Arch. Dermatol. Res. 290, 375-381.
5. Ando, H., Funasaka, Y., Oka, M., Ohashi, A., Furumura, M., Matsunaga, J., Matsunaga, N., Hearing, V.J., and Ichihashi, M. (1999). Possible involvement of proteolytic degradation of tyrosinase in the regulatory effect of fatty acids in melanogenesis. J. Lipids Res. 40, 1312-1316.
6. Ando, H., Watabe, H., Valencia, J., Yasumoto, K., Furumura, M., Funasaka, Y., Oka, M., Ichihashi, M., and Hearing, V.J. (2004). Fatty acids regulates pigmentation via proteasomal degradation of tyrosinase. J. Biol. Chem. 279, 15427-15433.
7. Ando, H., Wen, Z.M., Kim, H.Y. et al. (2006). Intracellular composition of fatty acid affects the processing and function of tyrosinase through the ubiquitin-proteasome pathway. Biochem. J. 394, 43-50.
8. Andrawis, A., and Khan, V. (1996). Effect of methimazole on the activity of mushroom tyrosinase. Biochem. J. 235, 91-96.
9. Au, W.Y., Yeung, C.K., Chan, H.H., and Lie, A.K. (2001). Generalized vitiligo after lymphocyte infusion for relapse leukaemia. Br. J. Dermatol. 145, 1015-1017.
10. Balina, L.M., and Graupe, K. (1991). The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int. J. Dermatol. 30, 893-895.
11. Barsh, G., Gunn, T., He, L., Schlossman, S., and Duke-Cohan, J. (2000). Biochemical and genetic studies of pigment-type switching. Pigment Cell. Res. 13 (Suppl. 8), 48-53.
12. Bian, S., Doh, H.J., Zheng, J., Kim, J.S., Lee, C.H., and Kim, D.D. (2003). In vitro evaluation of patch formulations for topical delivery of gentisic acid in rats. Eur. J. Pharmacol. Sci. 18, 141-147.
13. Boissy, R.E., Visscher, M., and DeLong, M.A. (2005). DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp. Dermatol. 8, 601-608.
14. Bolognia, J.L., Sodi, S.A., Osber, M.P., and Pawelek, J.M. (1995). Enhancement of the depigmenting effect of hydroquinone by cysteamine and buthionine sulfoximine. Br. J. Dermatol. 133, 349-357.
15. Bonilla, C., Boxill, L.A., Donald, S.A., Williams, T., Sylveste, N., Parra, E.J., Dios, S., Norton, H.L., Shriver, M.D., and Kittles, R.A. (2005). The 8818G allele of the agouti signaling protein (ASIP) gene is ancestral and is associated with darker skin color in African Americans. Hum. Genet. 116, 402-406.
16. Borovansky, J., and Elleder, M. (2003). Melanosome degradation: fact or fiction. Pigment Cell. Res. 16, 280-286.
17. Breathnach, A.S. (1996). Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid and other therapies. Cutis 57 (Suppl. 1), 36-45.
18. Breathnach, A., Martin, B., Nazzaro-Porro, M., Passi, S., Mann, P., Cooper, J., and Morpurgo, G. (1979). Effect of dicarboxylic acids on normal human melanocytes in dispersed tissue culture. Br. J. Dermatol. 101, 641-649.
19. Briganti, S., Camera, E., and Picardo, M. (2003). Chemical and Instrumental approaches to treat hyperpigmentation. Pigment Cell. Res. 16, 101-110.
20. Brown, T., Zirvi, M., Cotsarelis, G., and Gelfand, J.M. (2005). Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J. Am. Acad. Dermatol. 52, 715-716.
21. Carlson, J.A., Grabowski, R., Mu, X.C., Del Rosario, A., Malfetano, J., and Slominski, A. (2002). Possible mechanisms of hypopigmentation in lichen sclerosus. Am. J. Dermatopathol. 24, 97-107.
22. Carroll, J.M., Crompton, T., Seery, J.P., and Watt, F.M. (1997). Transgenic mice expressing IFN-gamma in the epidermis have eczema, hair hypopigmentation, and hair loss. J. Invest. Dermatol. 108, 412-422.
23. Chakraborty, A.K., Funasaka, Y., Komoto, M., and Ichihashi, M. (1998). Effect of arbutin on melanogenic proteins in human melanocytes. Pigment Cell. Res. 11, 206-212.
24. Chang, T.S., Ding, H.Y., and Lin, H.C. (2005). Identifying 6,7,4′-trihydroxyisoflavone as a potent tyrosinase inhibitor. Biosci. Biotechnol. Biochem. 69, 1999-2001.
25. Chen, Q.X., and Kubo, I. (2002). Kinetics of mushroom tyrosinase inhibition by quercetin. J. Agric. Food Chem. 50, 4108-4112.
26. Cho, S.M., Kwon, Y.M., Lee, J.H., Yon, K.H., and Lee, M.W. (2002). Melanogenesis inhibitory activities of diartylheptanoids from Alnus hirsuta Turcz in B16 mouse melanoma cells. Arch. Dermatol. Res. 25, 885-888.
27. Choi, S., Lee, S.K., Kim, J.E., Chung, M.H., and Park, Y.I. (2002a). Aloesin inhibits hyperpigmentation induced by UV radiation. Clin. Exp. Dermatol. 27, 513-515.
28. Choi, S.Y., Kim, S., Kim, H., Suk, K., Hwang, J.S., Lee, B.G., Kim, A.J., and Kim, S.Y. (2002b). (4-methoxy-benzyliden)-(3-methoxyphenyl)-amine, anitrogen analog of stilbene as a potent inhibitor of melanin production. Chem. Pharm. Bull. (Tokyo) 50, 450-452.
29. Choi, H., Ahn, S., Lee, B.G., Chang, I., and Hwang, J.S. (2005). Inhibition of skin pigmentation by an extract of Lepidium apetalum and its possible implications in IL-6 mediated signalling. Pigment Cell. Res. 18, 439-446.
30. Chun, H.J., Jeong, S.H., Woo, W.H., and Kim, H.K. (2001). Effect of ikarisoside A isolated from Epimedium koreanum on melanogenic. Bull. Korean Chem. Soc. 22, 1159-1162.
31. Costin, G.E., Trif, M., Nichita, N., Dwek, R.A., and Petrescu, S.M. (2002). pH-sensitive liposomes are efficient carriers for endoplasmic reticulum-targeted drugs in mouse melanoma cells. Biochem. Biophys. Res. Commun. 293, 918-923.
32. Cotelessa, C., Peris, K., Onorati, M.T., Fargnoli, M.C., and Chimenti, S. (1999). The use of chemical agents in the treatment of different cutaneous hyperpigmentations. J. Dermatol. Surg. 25, 450-454.
33. Couteau, C., and Coiffard, L.J. (2000). Photostability determination of arbutin, a vegetable whitening agent. Farmacology 55, 410-413.
34. Curto, E.V., Kwong, C., Hermersdorfer, H., Glatt, H., Santis, C., Virador, V., Hearing, V.J., and Dooley, T.P. (1999). Inhibitors of mammalian melanocytes tyrosinase: in vitro comparisons of alkyl esters of gentisic acid and other putative inhibitors. Biochem. Pharmacol. 15, 663-672.
35. De Luca, C., Picardo, M., Breathnach, A., and Passi, S. (1996). Lipoperoxidase activity of Pityrosporum: characterization of by-products and possible role in pityriasis versicolor. Exp. Dermatol. 5, 49-56.
36. Dogra, S., Kanwar, A.J., and Parsad, D. (2002). Adapalene in the treatment of melasma: a preliminary report. J. Dermatol. 29, 539-540.
37. Dooley, T.P., Gadwood, R.C., Kilgore, K., and Thomasco, L.M. (1994). Development of an in vitro primary screen for skin depigmentation and antimelanoma agents. Skin Pharmacol. 7, 188-200.
38. Dutkiewicz, R., Albert, D.M., and Levin, L.A. (2000). Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp. Eye Res. 70, 563-569.
39. Elleder, M., and Borovansky, J. (2001). Autofluorescence of melanins induced by ultraviolet radiation and near ultraviolet light. A histochemical and biochemical study. J. Mol. Histochem. 33, 273-281.
40. Ennes, S.B.P., Paschoalick, R.C., and Mota de Avelar, A.M. (2000). A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. J. Dermatol. Treat. 11, 173-179.
41. Espin, J.C., and Wichers, H.J. (2001). Effect of captopril on mushroom tyrosinase activity in vitro. Biochim. Biophys. Acta 1554, 289-300.
42. Fechner, G.A., Jacobs, J.J., and Parson, P.G. (1993). Inhibition of melanogenesis in human melanoma cells by novel analogues of the partial histamine (H2) agonist nordimaprit. Biochem. Pharmacol. 46, 47-54.
43. Ferioli, V., Rustichelli, G., Pavesi, G., and Gamberini, G. (2001). New combined treatment of hypermelanosis: analytical studies on efficacy and stability improvement. Int. J. Cosmet. Sci. 23, 333-340.
44. Fleischer, A.B., Schwartzel, E.H., Colby, S.I., and Altman, D.J. (2000). The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyper-pigmented lesions in two double-blind multicenter clinical studies. J. Am. Acad. Dermatol. 42, 459-467.
45. Fleming, C.J., Bryden, A.M., Evans, A., Dawe, R.S., and Ibbotson, S.H. (2004). A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br. J. Dermatol. 151, 458.
46. Fu, B., Li, H., Wang, X., Lee, F.S., and Cui, S. (2005). Isolation and identification of flavonoids in licorice and a study of their inhibitory effects on tyrosinase. J. Agric. Food Chem. 53, 7408-7414.
47. Fukuda, Y., Nagano, M., Tsukamoto, K., and Futatsuka, M. (1998). In vitro studies on the depigmenting activity of 4-(p-hydroxyphenyl)-2-butanone. J. Occup. Health. 40, 137-142.
48. Fuller, B.B., Drake, M.A., Spaulding, D.T., and Chaudhry, F. (2000). Downregulation of tyrosinase activity in human melanocyte cell cultures by yohimbine. J. Invest. Dermatol. 114, 268-276.
49. Funasaka, Y., Chakraborty, A.K., Komoto, M., Ohashi, A., and Ichihashi, M. (1999). The depigmenting effect of α-tocopheryl ferulate on human melanoma cells. Br. J. Dermatol. 141, 20-29.
50. Gallardo, M.J., and Johnson, D.A. (2004). Cutaneous hypopigmentation following a posterior sub-tenon triamcinolone injection. Am. J. Ophthalmol. 137, 779-780.
51. Garcia-Borron, J.C., Sanchez-Laorden, B.L., and Jimenez-Cervantes, C. (2005). Melanocortin-1 receptor structure and functional regulation. Pigment Cell. Res. 18, 393-410.
52. Griffiths, C.E., Finkel, L.J., Ditre, C.M., Hamilton, T.A., Ellis, C.N., and Voorhees, J.J. (1993). Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br. J. Dermatol. 129, 415-421.
53. Grimes, P.E. (1999). The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol. Surg. 25, 18-22.
54. Guevara, I.L., and Pandya, A.G. (2001). Melasma treated with hydroquinone, tretinoin and a fluorinated steroid. Int. J. Dermatol. 40, 212-215.
55. Hakozaki, T., Minwalla, L., Zhuang, J., Chloa, M., Matsubara, A., Miayamoto, K., Greatens, A., Hillebrand, G.G., Bissett, D.L., and Boissy, R.E. (2002). The effect of niaciamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br. J. Dermatol. 147, 20-31.
56. Hall, A.M., Krishnamoorthy, L., and Orlow, S.J. (2003). Accumulation of tyrosinase in the endolysosomal compartment is induced by U18666A. Pigment Cell. Res. 16, 149-158.
57. Hasan, S., Dinh, K., Lombardo, F., Dawkins, F., and Kark, J. (2003). Hypopigmentation in an African patient treated with imatinib mesylate: a case report. J. Natl Med. Assoc. 95, 722-724.
58. Hirobe, T. (2005). Role of keratinocyte-derived factors involved in regulating the proliferation and differentiation of mammalian epidermal melanocytes. Pigment Cell. Res. 18, 2-12.
59. Hu, D.N. (2000). Regulation of growth and melanogenesis of uveal melanocytes. Pigment Cell. Res. 13 (Suppl. 8), 81-86.
60. Huh, C.H., Seo, K.I., Park, J.Y., Lim, J.G., Eun, H.C., and Park, K.C. (2003). A randomized, double-blind, placebo-controlled trail of vitamin C iontophoresis in melasma. Dermatology 206, 316-320.
61. Inoue, S., Hasegawa, K., Ito, S., Ozeki, H., Solano, F., Jiménez-Cervantes, C., Wakamatsu, K., and Fujita, K. (1995). Antimelanoma effect of 4-S-cysteaminylcatechol, and activated form of 4-S-cysteaminylphenol. Cancer Res. 55, 2603-2607.
62. Jacques, S.L., and McAuliffe, D.J. (1991). The melanosome: threshold temperature for explosive vaporization and internal absorption coefficient during pulsed laser irradiation. Photochem. Photobiol. 53, 769-775.
63. Jappe, U., Geier, J., and Hausen, B.M. (2005). Contact vitiligo following a strong patch test reaction to triglycidyl-p-aminophenol in an aircraft industry worker: case report and review of the literature. Contact Derm. 53, 89-92.
64. Jeong, Y.M., Choi, Y.G., Kim, D.S., Park, S.H., Yoon, J.A., Kwon, S.B., Park, E.S., and Park, K.C. (2005). Cytoprotective effect of green tea extract and quercetin against hydrogen peroxide-induced oxidative stress. Arch. Pharm. Res. 28, 1251-1256.
65. Jimbow, K. (1991). N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch. Dermatol. 127, 1528-1534.
66. Jimbow, M., Marusyk, H., and Jimbow, K. (1995). The in vivo melanocytotoxicity and depigmenting potency of N-2,4-acetoxyphenyl thioethyl acetamide in the skin and hair. Br. J. Dermatol. 133, 526-536.
67. Jiménez-Cervantes, C., Martínez-Esparza, M., Pérez, C., Daum, N., Solano, F., and García-Borrón, J.C. (2001). Inhibition of melanogenesis in response to oxidative stress. Trasient downregulation of melanocyte differentiation markers and possible involvement of microphthalmia transcription factor. J. Cell. Sci. 114, 2335-2341.
68. Jones, K., Hughes, J., Hong, M., Jia, Q., and Orndorff, S. (2002). Modulation of melanogenesis by aloesin: a competitive inhibitor of tyrosinase. Pigment Cell. Res. 15, 335-340.
69. Joo, S.S., Kim, H.J., Kwon, H.S., and Lee, D.I. (2002). Augmentation of macrophage antitumor activities and nitric oxide production by oregonin. Arch. Pharm. Res. 25, 457-462.
70. Jordan, S.A., and Jackson, I.J. (1998). Melanocortin receptors and antagonists regulate pigmentation and body weight. Bioessays 20, 603-606.
71. Kageyama, A., Oka, M., Okada, T., Nakamura, S., Ueyama, T., Saito, N., Hearing, V.J., Ichihashi, M., and Nishigori, C. (2004). Downregulation of melanogenesis by phospholipase D2 through the ubiquitin proteasome-mediated degradation of tyrosinase. J. Biol. Chem. 279, 27774-27780.
72. Kameyama, K., Sakai, C., Kondoh, S. et al. (1996). Inhibitory effect of magnesium L-ascorbyl-2-phosphate on melanogenesis in vitro and in vivo. J. Am. Acad. Dermatol. 34, 29-33.
73. Kar, H.K. (2002). Efficacy of β-carotene topical application in melasma: an open clinical trial. Indian J. Dermatol. Venereol. Leprol. 68, 320-322.
74. Kashiwagi, K., Tsukamoto, K., Susuki, M., and Tsukahara, S. (2002). Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes. J. Glaucoma 11, 57-64.
75. Kasraee, K. (2002). Depigmentation of brown guinea pig skin by topical application of methimazole. J. Invest. Dermatol. 118, 205-207.
76. Kasraee, B., Tran, C., Sorg, O., and Saurat, J.H. (2005). The depigmenting effect of RALGA in C57BL/6 mice. Dermatology 210 (Suppl. 1), 30-34.
77. Khatib, S., Nerya, O., Musa, R., Shmuel, M., Tamir, S., and Vaya, J. (2005). Chalcones as potent tyrosinase inhibitors: the importance of a 2,4-substituted resorcinol moiety. Bioorg. Med. Chem. 13, 433-441.
78. Khunger, N., Sarkar, R., and Jain, R.K. (2004). Tretinoin peel versus glycolic peels in the treatment of melasma in dark-skinned patients. Dermatol. Surg. 30, 756-760.
79. Kim, Y.J., and Uyama, H. (2005). Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future. Cell. Mol. Life Sci. 62, 1707-1723.
80. Kim, D.S., Kim, S.Y., Chung, J.H., Kim, K.H., Eun, H.C., and Park, K.C. (2002a). Delayed ERK activation by ceramide reduces melanin synthesis in human melanocytes. Cell Signal. 14, 779-785.
81. Kim, Y.M., Yun, J., Lee, C.K., Lee, H., Min, K.R., and Kim, Y. (2002b). Oxyresveratrol and hydroxystilbene compounds. J. Biol. Chem. 277, 16340-16344.
82. Kim, D.H., Hwang, J.S., Baek, H.S., Kim, K.J., Lee, B.G., Chang, I., Kang, H.H., and Lee, O.S. (2003). (5-[3-aminopropyl)phosphinooxy]-2- (hydroxymethyl)-4H-1-pyran-4-on as a novel whitening agent. Chem. Pharm. Bull. (Tokyo) 51, 113-116.
83. Kim, D.S., Park, S.H., and Park, K.C. (2004a). Transforming growth factor-beta1 decreases melanin synthesis via delayed extracellular signal-regulated kinase activation. Int. Biochem. Cell Biol. 36, 1482-1491.
84. Kim, D.S., Park, S.H., Kwon, S.B., Li, K., Youn, S.W., and Park, K.C. (2004b). (-)Epigallocatechin-3-gallate and hinokitiol reduce melanin synthesis via decreased MITF production. Arch. Pharm. Res. 27, 334-339.
85. Kim, D.S., Park, S.H., Kwon, S.B., Youn, S.W., and Park, K.C. (2004c). Effects of lysophosphatidic acid on melanogenesis. Chem. Phys. Lipids 127, 199-206.
86. Kim, D.S., Kim, S.Y., Park, S.H., Choi, Y.G., Kwon, S.B., Kim, M.K., Na, J.I., Youn, S.W., and Park, K.C. (2005a). Inhibitory effects of 4-n-butylresorcinol on tyrosinase activity and melanin synthesis. Biol. Pharm. Bull. 28, 2216-2219.
87. Kim, D.S., Park, S.H., Kwon, S.B., Park, E.-S., Huh, C.-H., Youn, S.W., and Park, K.C. (2005b). Sphingosylphosphorylcholine-induced ERK activation inhibits melanin synthesis in human melanocytes. Pigment Cell. Res. 19, 146-153.
88. Kim, H.J., Seo, S.H., Lee, B.G., and Lee, Y.S. (2005c). Identification of tyrosinase inhibitors from Glycyrrhiza uralensis. Planta Med. 71, 785-787.
89. Kim, Y.J., No, J.K., Lee, J.H., and Chung, H.Y. (2005d). 4,4′-dihydroxybiphenyl as a new potent tyrosinase inhibitor. Biol. Pharm. Bull. 28, 323-327.
90. Kim, D., Park, J., Kim, J., Han, C., Yoon, J., Kim, N., Seo, J., and Lee, C. (2006a). Flavonoids as mushroom tyrosinase inhibitors: a fluorescence quenching study. J. Agric. Food Chem. 54, 935-941.
91. Kim, K.S., Kim, J.A., Eom, S.Y., Lee, S.H., Min, K.R., and Kim, Y. (2006b). Inhibitory effect of piperlonguminine on melanin production in melanoma B16 cell line by downregulation of tyrosinase expression. Pigment Cell. Res. 19, 90-98.
92. Kim, Y.J., No, J.K., Lee, J.H., and Chung, H.Y. (2006c). 3,4-dihydroxyacetophenone: inhibition of tyrosinase and MITF. Biosci. Biotechnol. Biochem. 70, 532-534.
93. Kimbrough-Green, C.K., Griffiths, C.E., Finkel, L.J., Hamilton, T.A., Bulengo-Ransby, S.M., Ellis, C.N., and Voorhees, J.J. (1994). Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch. Dermatol. 30, 727-733.
94. Kligman, D.E. (2004). Tretinoin peels versus glycolic peels. Dermatol. Surg. 30, 1609.
95. Kligman, A.M., and Willis, I. (1975). A new formula for depigmenting human skin. Arch. Dermatol. 111, 40-48.
96. Krasagakis, K., Garbe, C., Eberle, J., and Orfanos, C.E. (1995). Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro. Arch. Dermatol. Res. 287, 259-265.
97. Kroll, T.M., Bommiasamy, H., Boissy, R.E., Hernandez, C., Nickoloff, B.J., Mestril, R., and Le Poole, I.C. (2005). 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J. Invest. Dermatol. 124, 798-806.
98. Kubo, I., and Kinst-Hori, I. (1999). Flavonols from saffron flower: tyrosinase inhibitory activity and inhibition mechanism. J. Agric. Food Chem. 47, 4121-4125.
99. Kubo, I., Kinst-Hori, I., and Yokokawa, Y. (1994). Tyrosinase inhibitors from Anacardium occidentale fruits. J. Nat. Prod. 57, 545-551.
100. Kubo, I., Kinst-Hori, I., Kubo, Y., Yamagiwa, Y., Kamikawa, Y., Kamikawa, T., and Karaguchi, H. (2000). Molecular design of antibrowning agents. J. Agric. Food Chem. 48, 1393-1399.
101. Kumar, P., and Adolph, S. (1998). Hypopigmentation along subcutaneous veins following intrakeloid triamcinolone injection: a case report and review of literature. Burns 24, 487-488.
102. Lassalle, M.W., Igarashi, S., Sasaki, M., Wakamatsu, K., Ito, S., and Horikoshi, T. (2003). Effects of melanogenesis-inducing nitric oxide and histamine on the production of eumelanin and pheomelanin in cultured human melanocytes. Pigment Cell. Res. 16, 81-84.
103. Lee, K.K., and Choi, J.D. (1999). The effect of Areca catechu L. extract on anti-inflammation and anti-melanogenesis. Int. J. Cosmet. Sci. 21, 275.
104. Lee, S.H., Choi, S.Y., Kim, H., Hwang, J.S., Lee, B.G., Gao, J.J., and Kim, S.Y. (2002a). Mulberroside F isolated from the leaves of Morus alba inhibits melanin biosynthesis. Biol. Pharm. Bull. 25, 1045-1048.
105. Lee, M.H., Kim, H.J., Ha, D.J., Paik, J.H., and Kim, H.Y. (2002b). Therapeutic effect of topical application of linoleic acid and lyncomicin in combination with betamethasone valerate in melasma patients. J. Korean Med. Sci. 17, 518-523.
106. Lee, K.T., Lee, K.S., Jeong, J.H., Jo, B.K., Heo, M.Y., and Kim, H.P. (2003). Inhibitory effects of Ramulus mori extracts on melanogenesis. J. Cosmet. Sci. 54, 133-142.
107. Lee, N.K., Son, K.H., Chang, H.W., Kang, S.S., Park, H., Heo, M.Y., and Kim, H.P. (2004). Prenylated flavonoids as tyrosinase inhibitors. Arch. Pharm. Res. 27, 1132-1135.
108. Lee, Y.S., Park, J.H., Kim, M.H., Seo, S.H., and Kim, H.J. (2006). Synthesis of tyrosinase inhibitory kojic acid derivative. Arch. Pharm. Chem. Life Sci. 339, 111-114.
109. Leenutaphong, V., Nettakul, A., and Rattanasuwon, P. (1999). Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial. J. Med. Assoc. Thai. 82, 868-875.
110. Legros, L., Cassuto, J.P., and Ortonne, J.P. (2005). Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo? Br. J. Dermatol. 153, 691-692.
111. Levy, J.L., Pons, F., Agopian, L., and Besson, R. (2005). A double-blind controlled study of a nonhydroquinone bleaching cream in the treatment of melasma. J. Cosmet. Dermatol. 4, 272-276.
112. Lim, J.T. (1999). Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol. Surg. 25, 282-284.
113. Lim, J.T., and Than, S.N. (1997). Glycolic acid peels in the treatment of melasma among Asian women. Dermatol. Surg. 23, 177-179.
114. Lin, S.C. (2005). Studies on the Supercritical Carbon dioxide Extraction of the Herbal Medicine and its Extract for Inhibition of Melanin Formation. Master Thesis, etd-0216105-253042.pdf. Electronic Thesis Dissertations database (ETD-db). http://etdncku.lib.ncku.edu.tw/ETD-db.
115. Lin, C.B., Babiarz, L., Liebel, F., Price, E.R., Kizoulis, M., Gendimenico, G.J., Fisher, D.E., and Seiberg, M. (2002). Modulation of microphthalmia-associated transcription factor gene expression alters skin pigmentation. J. Invest. Dermatol. 119, 1330-1340.
116. Lozano, C., Torres, J.L., Julia, L., Jiménez, A., Cntelles, J.J., and Cascante, M. (2005). Effect of new antioxidant cysteinyl-flavanol conjugated on skin cancer cells. FEBS Lett. 579, 4219-4225.
117. Luiten, R.M., Kueter, E.W., Mooi, W. et al. (2005). Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J. Clin. Oncol. 23, 829-831.
118. Maeda, K., and Fukuda, M. (1996). Arbutin: mechanism of its depigmenting action in human melanocyte culture. J. Pharmacol. Exp. Ther. 276, 765-769.
119. Maeda, K., and Naganuma, M. (1998). Topical trans-4- aminomethylcyclohexanecarboxylic acid present ultraviolet radiation-induced pigmentation. J. Photochem. Photobiol. 47, 136-141.
120. Maeda, K., Tomita, Y., Naganuma, M., and Tagami, H. (1996). Phospholipases induce melanogenesis in organ-cultured skin. Photochem. Photobiol. 64, 220-223.
121. Maresca, V., Roccella, M., Roccella, F., Camera, E., Del Porto, G., Passi, S., Grammatico, P., and Picardo, M. (1997). Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J. Invest. Dermatol. 109, 310-313.
122. Maresca, V., Flori, E., Cardinali, G., Briganti, S., Lombardi, D., Mileo, A.M., Paggi, M.G., and Picardo, M. (2006). Ferritin light Chain down-modulation generates depigmentation in human metastatic melanoma cells by influencing tyrosinase maturation. J. Cell. Physiol. 206, 843-848.
123. Martinez-Esparza, M., Jimenez-Cervantes, C., Solano, F., Lozano, J.A., and Garcia-Borron, J.C. (1998). Mechanisms of melanogenesis inhibition by tumor necrosis factor-alpha in B16/F10 mouse melanoma cells. Eur. J. Biochem. 255, 139-146.
124. Martinez-Esparza, M., Solano, F., and Garcia-Borron, J.C. (1999). Independent regulation of tyrosinase by the hypopigmenting cytokines TGFβ1 and TNF alpha and the melanogenic hormone α-MSH in B16 mouse melanocytes. Cell. Mol. Biol. 45, 991-1000.
125. Martinez-Esparza, M., Ferrer, C., Castells, M.T., Garcia-Borron, J.C., and Zuasti, A. (2001). Transforming growth factor beta1 mediates hypopigmentation of B16 mouse melanoma cells by inhibition of melanin formation and melanosome maturation. Int. J. Biochem. Cell. Biol. 33, 971-983.
126. Mastore, M., Kohler, L., and Nappi, A.J. (2005). Production and utilization of hydrogen peroxide associated with melanogenesis and tyrosinase-mediated oxidations of DOPA and dopamine. FEBS J. 272, 2407-2415.
127. Matsuda, H., Nakamura, S., and Kubo, M. (1994). Studies of cuticle drugs from natural sources. II. Inhibitory effects of Prunus plants on melanin biosynthesis. Biol. Pharm. Bull. 17, 1417-1420.
128. Matsuda, H., Higashino, M., Chen, W., Tosa, H., Iinuma, M., and Kubo, M. (1995). Studies of cuticle drugs from natural sources. III. Inhibitory effect of Myrica rubra on melanin biosynthesis. Biol. Pharm. Bull. 18, 1148-1150.
129. Matsuda, H., Higashino, M., Nakai, Y., Iinuma, M., Kubo, M., and Lang, F.A. (1996). Studies of cuticle drugs from natural sources. IV. Inhibitory effects of some Arctostaphylos plants on melanin biosynthesis. Biol. Pharm. Bull. 19, 153-156.
130. Matsuda, H., Hirata, N., Kawaguchi, Y., Yamazaki, M., Naruto, S., Shibano, M., Taniguchi, M., Baba, K., and Kubo, M. (2005). Melanogenesis stimulation in murine B16 melanoma cells by umberiferae plant extracts and their coumarin constituents. Biol. Pharm. Bull. 28, 1229-1233.
131. Matsuo, M., Sasaki, N., Saga, K., and Kaneko, T. (2005). Cytotoxicity of flavonoids toward cultured normal human cells. Biol. Pharm. Bull. 28, 253-259.
132. McEwan, M.T., and Parson, P.G. (1991). Regulation of tyrosinase expression and activity in human melanoma cells via histamine receptors. J. Invest. Dermatol. 97, 868-873.
133. McGovern, S.L., and Stoichet, B.K. (2003). Kinase inhibitors. Not just for kinases anymore. J. Med. Chem. 46, 1478-1483.
134. Menter, A. (2004). Rationale for the use of topical corticosteroids in melasma. J. Drugs Dermatol. 3, 169-174.
135. Minwalla, L., Zhao, Y., Cornelius, J., Babcock, G.F., Wickett, R.R., Le Poole, C., and Boissy, R.E. (2001). Inhibition of melanosome transfer from melanocytes to keratinocytes by lectins and neoglycoproteins in an in vitro model system. Pigment Cell. Res. 14, 185-194.
136. Motokawa, T. (2003). Inulavosin, a new type of melanogenesis inhibitor, promote tyrosinase degradation. Pigment Cell. Res. 16, 594.
137. Mun, Y.J., Lee, S.W., Jeong, H.W., Lee, K.G., Kim, J.H., and Woo, W.H. (2004). Inhibitory effect of miconazole on melanogenesis. Biol. Pharm. Bull. 27, 806-809.
138. Nagata, H., Takekoshi, S., Takeyama, R., Takao, H., and Osamura, R.Y. (2004). Quercetin enhances melanogenesis by increasing the activity and synthesis of tyrosinase in human melanoma cells and in normal human melanocytes. Pigment Cell. Res. 17, 66-73.
139. Nair, X., Parah, P., Suhr, L., and Tramposch, K.M. (1993). Combination of 4-hydroxyanisole and all trans retinoic acid produces synergistic skin depigmentation in swine. J. Invest. Dermatol. 101, 145-149.
140. Naish, S., and Riley, P.A. (1989). Studies on the kinetics of oxidation of 4-hydroxyanisole by tyrosinase. Biochem. Pharmacol. 38, 1103-1107.
141. Nakagawa, M., and Kawai, K. (1995). Contact allergy to kojic acid in skin care products. Contact Dermatitis. 32, 9-13.
142. Nakajima, M., Shinoda, I., Samejima, Y., Miyauchi, H., Fukuwatari, Y., and Hayasawa, H. (1996). κ-casein suppresses melanogenesis in cultured pigment cells. Pigment Cell. Res. 9, 235-239.
143. Nakajima, M., Shinoda, I., Mikogami, T., Iwamoto, H., Hashimoto, S., Miyauchi, H., Fukuwatari, Y., and Hayasawa, H. (1997). β-lactoglobulin suppresses melanogenesis in cultured human melanocytes. Pigment Cell. Res. 10, 410-413.
144. Nakamura, K., Yoshida, M., Uchiwa, H., Kawa, Y., and Mizoguchi, M. (2003). Down-regulation of melanin synthesis by a diphenyl derivative and its mechanism. Pigment Cell. Res. 16, 494-500.
145. Nanda, V., Parwaz, M.A., and Handa, S. (2006). Linear hypopigmentation alter triamcinolone injection: a rare complication of a common procedure. Aesthetic. Plast. Surg. 30, 118-119.
146. Nazzaro-Porro, M., Passi, S., Balus, L., Breathnach, A., Martin, B., and Morpurgo, G. (1979). Effect of dicarboxylic acids on lentigo maligna. J. Invest. Dermatol. 72, 296-305.
147. Nazzaro-Porro, M., Passi, S., Zina, G., and Breathnach, A.S. (1989). Then year's experience of treating lentigo maligna with topical azelaic acid. Acta Derm. Venereol. (Stockh.) Suppl. 143, 49-57.
148. Nerya, O., Musa, R., Khatib, S., Tamir, S., and Vaya, J. (2004). Chalcones as potent tyrosinase inhibitors: the effect of hydroxyl positions and numbers. Phytochemistry 65, 1389-1395.
149. Ni, Z., Mu, Y., and Gulati, O. (2002). Treatment of melasma with pyogenol. Phytother. Res. 16, 567-571.
150. Ni-Komatsu, L., Leung, J.K., Williams, D., Min, J., Khersonsky, S.M., Chang, Y.T., and Orlow, S.J. (2005). Triazine-based tyrosinase inhibitors identified by chemical genetic screening. Pigment Cell. Res. 18, 447-453.
151. Nihal, M., Ahmad, N., Mukhtar, H., and Wood, G.S. (2005). Antiproliferative and propapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int. J. Cancer 114, 513-521.
152. Njoo, M.D., Westerhof, W., Bos, J.D., and Bossuyt, P.M. (1999). The development of guideline for the treatment of vitiligo. Arch. Dermatol. 135, 1514-1521.
153. No, J.K., Soung, D.Y., Kim, Y.J., Shim, K.H., Jun, Y.S., Rhee, S.H., Yokozawa, T., and Chung, H.Y. (1999). Inhibition of tyrosinase by green tea components. Life Sci. Pharmacol. Lett. 65, 241-246.
154. No, J.K., Kim, Y.J., Lee, J.S., and Chung, H.Y. (2006). Inhibition of melanogenic activity by 4,4′-dihydroxybiphenyl in melanoma cells. Biol. Pharm. Bull. 29, 14-16.
155. Ohguchi, K., Tanaka, T., Ilyya, I., Ito, T., Iinuma, M., Matsumoto, K., Asao, Y., and Nozawa, Y. (2003a). Gnetol as a potent tyrosinase inhibitor from genus Gnetum. Biosci. Biotechnol. Biochem. 67, 663-665.
156. Ohguchi, K., Tanaka, T., Kido, T., Baba, K., Iinuma, M., Matsumoto, K., Akao, Y., and Nozawa, Y. (2003b). Effects of hydroxystilbene derivatives on tyrosinase activity. Biochem. Biophys. Res. Commun. 307, 861-863.
157. Ohguchi, K., Akao, Y., and Nozawa, Y. (2005). Involvement of calpain in melanogenesis of mouse B16 melanoma cells. Mol. Cell. Biochem. 275, 103-107.
158. Okombi, S., Rival, D., Bonnet, S., Mariotte, A.M., Perrier, E., and Boumendjel, A. (2006a). Discovery of benzylidenebenzofuran-3(2H)-one (aurones) as inhibitors of tyrosinase derived from human melanocytes. J. Med. Chem. 49, 329-333.
159. Okombi, S., Rival, D., Bonnet, S., Mariotte, A.M., Perrier, E., and Boumendjel, A. (2006b). Analogues of N-hydroxycinnamoylphenalkylamides as inhibitors of human melanocyte-tyrosinase. Bioorg. Med. Chem. Lett. 16, 2252-2255.
160. Olander, K., Larsson, B., and Dencker, L. (1983). Thioamides as false melanin precursors: studies in murine melanomas. Acta Pharmacol. Toxicol. 52, 135-142.
161. Orlow, S., Chakraborty, A.K., Boissy, R., and Pawelek, J. (1990). Inhibition of induced melanogenesis in Cloudman melanoma cells by for phenotype modifiers. Exp. Cell. Res. 191, 209-218.
162. Ortonne, J.P., and Passeron, T. (2005). Melanin pigmentary disorders: treatment update. Dermatol. Clin. 23, 209-226.
163. Ortonne, J.P., Camacho, F., Wainwright, N., Bergfelt, L., Westerhof, W., and Roseeuw, D. (2004). Safety and efficacy of combined use of 4-hydroxyanisole (mequinol) 2%/tretinoin 0.01% solution and sunscreen in solar lentigines. Cutis 74, 67-72.
164. Park, S.H., Kim, D.S., Kim, W.G., Ryoo, I.J., Lee, D.H., Huh, C.H., Yiun, S.W., Yoo, I.D., and Park, K.C. (2004). Terrein: a new melanogenic inhibitor and its mechanism. Cell. Mol. Life Sci. 61, 2878-2885.
165. Passi, S., Picardo, M., Zompetta, C., De Luca, C., Breathnach, A.S., and Nazzaro-Porro, M. (1991a). The oxyradical-scavenging activity of azelaic acid in biological systems. Free Radic. Res. Commun. 15, 17-28.
166. Passi, S., Picardo, M., De Luca, C., Breathnach, A.S., and Nazzaro-Porro, M. (1991b). Scavenging activity of azelaic acid on hydroxyl radicals 'in vitro'. Free Radic. Res. Commun. 11, 329-338.
167. Pervaiz, S., and Clement, M.V. (2002). Hydrogen-peroxide-induced apoptosis: oxidative or reductive stress. Methods Enzymol. 352, 150-159.
168. Piao, L.Z., Park, H.R., Park, Y.K., Lee, S.K., Park, J.H., and Park, M.K. (2002). Mushroom tyrosinase inhibition activity of some chromones. Chem. Pharm. Bull. Tokyo 50, 309-311.
169. Podobinska, M., Krämer, H.J., Bartsch, A. et al. (2003). A cytotoxic metabolite from Malassezia furfur. Isolation and chemical identification as malassezin. Arch. Dermatol. Res. 294, 512.
170. Prince, S., Illing, N., and Kidson, S.H. (2001). SV-40 large T antigen reversibly inhibits expression of tyrosinase, TRP-1, TRP-2 and Mitf, but not Pax-3, in conditionally immortalized mouse melanocytes. Cell. Biol. Int. 25,
171. Raanani, P., Goldman, J.M., and Ben-Bassat, I. (2002). Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J. Clin. Oncol. 20, 869-870.
172. Rees, J.L. (2003). Genetics of hair and skin color. Annu. Rev. Genet. 37, 67-90.
173. Researching Committee of Rucinol (1999). The study on the efficacy of Rucinol (4-N-butylresorcinol) in chloasma. Nishinihon J. Dermatol. 61, 66.
174. Rigoni, C., Toffolo, P., Serri, R., and Caputo, R. (1989). Use of a cream based on 20% azelaic acid in the treatment of melasma. G. Ital. Dermatol. Venereol. 124, I-VI.
175. Riley, P.A. (1969). Hydroxyanisole depigmentation: in-vitro studies. J. Pathol. 97, 193-206.
176. Saeki, Y., Kanamaru, A., Matsumoto, A., and Tada, A. (2003). The inhibitory effects of centaureidin on the outgrowth of dendrites, melanosome transfer and melanogenesis in normal human melanogenesis. Pigment Cell. Res. 16, 593.
177. Saliou, C., Kitazawa, M., MacLaughlin, L., Yang, J.P., Lodge, J.K., Tetsuka, T., Iwasaki, K., Gillard, J., Okamoto, T., and Parker, L. (1999). Antioxidants modulate acute solar ultraviolet radiation-induced NF-kappa-B activation in a human keratinocyte cell line. Free Radic. Biol. Med. 26, 174-183.
178. Sánchez-Laorden, B.L., Sánchez-Más, J., Martínez-Alonso, E., Martínez-Menárguez, J.A., García-Borrón, J.C., and Jiménez-Cervantes, C. (2006). Dimerization of the human malanocortin 1 receptor: functional consequences and dominant-negative effects. J. Invest. Dermatol. 126, 172-181.
179. Sarkar, R., Bhalla, M., and Kanwar, A.J. (2002). A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology 205, 249-254.
180. Schioth, H.B., Phillips, S.R., Rudzish, R., Birch-Machin, M.A., Wikberg, J.E., and Rees, J.L. (1999). Loss of function mutations of the human melanocortin 1 receptor are common and are associated with red hair. Biochem. Biophys. Res. Commun. 260, 488-491.
181. Sefton, J., Kligman, A.M., Kopper, S.C., Lue, J.C., and Gibson, J.R. (2000). Photodamage pilot study: a double-blind, vehicle-controlled study to assess the efficacy and safety of tarazotene 0.1% gel. J. Am. Acad. Dermatol. 43, 656-663.
182. Seiberg, M., Paine, C., Sharlow, E., Andrade-Gordon, P., Costanzo, M., Eisinger, M., and Shapiro, S.S. (2000a). Inhibition of melanosome transfer results in skin lightening. J. Invest. Dermatol. 115, 162-167.
183. Seiberg, M., Paine, C., Sharlow, E., Andrade-Gordon, P., Costanzo, M., Eisinger, M., and Shapiro, S.S. (2000b). The protease-activated receptor 2 regulates pigmentation via keratinocytes-melanocyte interactions. Exp. Cell. Res. 254, 25-32.
184. Seo, S.Y., Sharma, V.K., and Sharma, N. (2003). Mushroom tyrosinase: recent prospects. J. Agric. Food Chem. 51, 2837-2853.
185. Sharma, A., Vora, A., and Bhutani, M. (2005). Generalized hypopigmentation due to imatinib: a fairness boon? Indian J. Dermatol. Venereol. Leprol. 71, 45-46.
186. Shimizu, K., Kondo, R., Sakai, K., Lee, S.H., and Sato, H. (1998). The inhibitory components from Artocapus incisus on melanin biosynthesis. Planta Med. 64, 408-412.
187. Shimizu, K., Kondo, R., Sakai, K., Takeda, N., Nagahata, T., and Oniki, T. (2001). Novel vitamin E derivative with 4-substituted resorcinol moiety has both antioxidant and tyrosinase inhibitory properties. Lipids 36, 1321-1326.
188. Shimogaki, H., Tanaka, Y., Tamai, H., and Masuda, M. (2000). In vitro and in vivo evaluation of ellagic acid on melanogenesis inhibition. Int. J. Cosmet. Sci. 22, 291-303.
189. Shoji, T., Masumoto, S., Moriichi, N., Kobori, M., Kanda, T., Shinmoto, H., and Tsushida, T. (2005). Procyanidin trimers to pentamers fractionated from apple inhibit melanogenesis in B16 mouse melanoma cells. J. Agric. Food Chem. 53, 6105-6111.
190. Slominski, A., Paus, R., and Bomirski, A. (1989). Hypothesis: possible role for the melatonin receptor in vitiligo: discussion paper. J. R. Soc. Med. 82, 539-541.
191. Slominski, A., Tobin, D.J., Shibahara, S., and Worstman, J. (2004). Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev. 84, 1155-1228.
192. Slominski, A., Plonka, P.M., Pisarchik, A., Smart, J.L., Tolle, V., Wortsman, J., and Low, M.J. (2005). Preservation of eumelanin hair pigmentation in proopiomelanocortin-deficient mice on a nonagouti (a/a) genetic background. Endocrinology 146, 1245-1253.
193. Smart, J.L., and Low, M.J. (2003). Lack of proopiomelanocortin peptides results in obesity and defective adrenal function but normal melanocyte pigmentation in the murine C57BL/6 genetic background. Ann. N. Y. Acad. Sci. 994, 202-210.
194. Smith, W. (1999). The effect of topical L(+)lactic acid and ascorbic acid on skin whitening. Int. J. Cosmet. Sci. 21, 33-40.
195. Solano, F., Gómez, D., Mayordomo, L., and Benaiges, A. (2005). Hypopigmented properties of epicatechin-cysteamine, hypoxosides and gypenosides. Pigment Cell. Res. 18 (Suppl. 1), 19.
196. Son, J.K., Park, J.S., Kim, J.A., Kim, Y., Chung, S.R., and Lee, S.H. (2003). Prenylated flavonoids from the roots of Sophora flavecens with tyrosinase inhibitory activity. Planta. Med. 69, 559-561.
197. Sprong, H., Degroote, S., Claeseens, T., Van Drunen, J., Oorschot, V., Westerink, B.H.C., Hiravayashi, Y., Kumperman, J., Van der Sluijs, P., and Van Meer, G. (2001). Glycosphingolipids are required for sorting melanosomal proteins in the Golgi complex. J. Cell. Biol. 155, 369-379.
198. Steingrimsson, E., Copeland, N.G., and Jenkins, N.A. (2004). Melanocytes and the microphthalmia transcription factor network. Annu. Rev. Genet. 38, 365-411.
199. Sugimoto, K., Nishimura, T., Nomura, K., Sugimoto, K., and Kuriki, T. (2003). Syntheses of arbutin-α-glycosides and a comparison of their inhibitory effects with those of α-arbutin and arbutin on human tyrosinase. Chem. Pharm. Bull. (Tokyo) 51, 798-801.
200. Swinehart, J.M. (1992). Salicylic acid ointment peeling of the hands and forearms. Effective nonsurgical removal of pigmentede lesions and actinic damage. J. Dermatol. Surg. Oncol. 18, 495-498.
201. Swope, V.B., Abdel-Malek, Z., Kassem, L.M., and Nordlund, J.J. (1991). Interleukins 1a and 6 and TNF-α are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J. Invest. Dermatol. 96, 180-185.
202. Swope, V.B., Sauder, D.N., McKenzie, R.C., Sramkoski, R.M., Krug, K.A., Babcock, G.F., Nordlund, J.J., and Abdel-Malek, Z.A. (1994). Synthesis of interleukin-1a and b by normal human melanocytes. J. Invest. Dermatol. 102, 749-753.
203. Tadokoro, T., Rouzaud, F., Itami, S., Hearing, V.J., and Yoshikawa, K. (2003). The inhibitory effect of androgen and sex-hormone binding globulin on the intracellular cAMP level and tyrosinase activity of normal human melanocytes. Pigment Cell. Res. 16, 190-197.
204. Takeyama, R., Takekoshi, S., Nagata, H., Osamura, R.Y., and Kawana, S. (2004). Quercetin-induced melanogenesis in a reconstituted three-dimensional human epidermal model. J. Mol. Histol. 35, 157-165.
205. Takizawa, T., Mitsumori, K., Tamura, T., Nasu, M., Ueda, M., Imai, T., and Hirose, M. (2003). Hepatocellular tumor induction in heterozygous p53-deficient CBA mice by a 26-week dietary administration of kojic acid. Toxicol. Sci. 73, 287-293.
206. Taylor, S.C., Torok, H., Jones, T. et al. (2003). Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 72, 67-72.
207. Theron, E.J., Albrecht, C.F., Kruger, P.B., Jenkins, K., and Merwe, M.J. (1994). β-glucosidase activity in fetal bovine serum renders the plant glucoside, hypoxoside, cytotoxic toward B16-F10-Bl-6 mouse melanoma cells. In. Vitro. Cell. Dev. Biol. Anim. 30A, 115-119.
208. Thoma, W., Krämer, H.-J., and Maysert, P. (2005). Pityriasis versicolor alba. JEADV 19, 147-152.
209. Torok, H., Taylor, S., Baumann, L. et al. (2005). A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J. Drugs Dermatol. 4, 592-597.
210. Tsao, H., Millman, P., Linette, G.P., Hodi, F.S., Sober, A.J., Goldberg, M.A., and Haluska, F.G. (2002). Hypopigmentation associated with adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch. Dermatol. 138, 799-802.
211. Tsao, A.S., Kantarjian, H., Cortes, J., O'Brien, S., and Talpaz, M. (2003). Imatinib mesylate causes hypopigmentation in the skin. Cancer 98, 2483-2487.
212. Tsuji-Naito, K., Hatani, T., Okada, T., and Tehara, T. (2006). Evidence for covalent lipoyl adduction with dopaquinone following tyrosinase-catalyzed oxidation. Biochem. Biophys. Res. Commun. 343, 15-20.
213. Vance, K.W., and Goding, C.R. (2004). The transcription network regulating melanocyte development and melanoma. Pigment Cell. Res. 17, 318-325.
214. Verallo-Rowell, V.M., Verallo, V., Graupe, K., Lopez-Villafuerte, L., and Garcia-Lopez, M. (1989). Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm. Venereol. Suppl. (Stockh.) 143, 58-61.
215. Voisey, J., and van Daal, A. (2002). Agouti: from mouse to man, from skin to fat. Pigment Cell. Res. 15, 10-18.
216. Wolff, G.L. (2003). Regulation of yellow pigment formation in mice: a historical perspective. Pigment Cell. Res. 16, 2-15.
217. Yagi, A., Kabash, A., Okamura, N., Haraguchi, H., Moustafa, S.M., and Khalifa, T.I. (2002). Antioxidant, free radical scavenging and anti-inflammatory effects of aloesin derivatives in Aloe vera. Planta. Med. 68, 957-960.
218. Yamaguchi, Y., Itami, S., Watabe, H., Yasumoto, K., Abdel-Malek, Z.A., Kubo, T., Rouzaud, F., Tanemura, A., Yoshikawa, K., and Hearing, V.J. (2004). Mesenchymal-epithelial interactions in the skin: increased expression of dickkopf1 by palmoplantar fibroblasts inhibits melanocyte growth and differentiation. J. Cell. Biol. 165, 275-285.
219. Yamakoshi, J., Otsuka, F., Sano, A., Tokutake, S., Saito, M., Kikuchi, M., and Kubota, Y. (2003). Lightening effect on ultraviolet-induced pigmentation of guinea pig skin by oral administration of a proanthocyanidin-rich extract from grape seeds. Pigment Cell. Res. 16, 629-638.
220. Yamamura, T., Onishi, J., Nishiyama, T. (2002). Antimelanogenic activity of hydrocoumarins in cultured normal human melanocytes by stimulating intracellular glutathione synthesis. Arch. Dermatol. Res. 294, 349-354.
221. Yeager, A.M., Shinn, C., Farmer, E.R., Wingard, J.R., and Yeager, M.J. (1992). Growth retardation and depigmentation of hair after high-dose busulfan and congenic hematopoietic cell transplantation in mice. Bone Marrow Transplant. 9, 199-204.
222. Yee, C., Thompson, J.A., Roche, P., Byrd, D.R., Lee, P.P., Piepkorn, M., Kenyon, K., Davis, M.M., Riddel, S.R., and Greenberg, P.D. (2000). Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T-cell mediated vitigo. J. Exp. Med. 192, 1637-1644.
223. Yokota, T., Nishio, H., Kubota, Y., and Mizoguchi, M. (1998). The inhibitory effect of glabridin from liquorice extracts on melanogenesis and inflammation. Pigment Cell. Res. 11, 355-361.
224. Yoon, T.J., and Hearing, V.J. (2003). Co-culture of mouse epidermal cells for studies of pigmentation. Pigment Cell. Res. 16, 159-163.
225. 2 receptors in normal human melanocytes. J. Invest. Dermatol. 114, 334-342.
226. Yoshimura, M., Watanabe, Y., Kasai, K., Yamakoshi, J., and Koga, T. (2005). Inhibitory effect of an ellagic acid-rich pomegranate extract on tyrosinase activity and ultraviolet-induced pigmentation. Biosci. Biotechnol. Biochem. 69, 2368-2373.
227. Yu, J., Wang, L., Walzem, R.L., Miller, E.G., Pike, L.M., and Patil, B.S. (2005). Antioxidant activity of citrus limonoids, flavonoids and coumarins. J. Agric. Food Chem. 53, 2009-2014.
228. Yung, G.D., Yang, J.Y., Song, E.S., and Park, J.W. (2001). Stimulation of melanogenesis by glycyrrhizin in B16 melanoma cells. Exp. Mol. Med. 33, 131-135.
229. Zaumseil, R.P., and Graupe, K. (1995). Topical azelaic acid in the treatment of melasma: pharmacological and clinical considerations. In Melasma. New Approaches to Therapy, M. Dunitz, ed. (London), pp. 19-41.